ClinicalTrials.gg
RecruitingNCT06462963SPRINTUpdated Aug 1, 2025

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

An interventional study of single-fraction SBRT and multiple-fraction SBRT in Breast Cancer, Prostate Cancer and NSCLC, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Recruiting at 15 sites in 4 countries. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
302
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Breast Neoplasms by European Organisation for Research and Treatment of Cancer - EORTC — 3 open to participants now, 5 under way, 2 of them phase 3. Breast Neoplasms · European Organisation for Research and Treatment of Cancer - EORTC.

Planned enrollment
10th of 28
302 · median 116
Started
2025
the only one that year
No phase
3 of 35
1 open now
Registered
35th of 35
by date

Among the 35 studies in Breast Neoplasms by European Organisation for Research and Treatment of Cancer - EORTC, this one is the 10th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2025, is one of 3 with no phase, and was the 35th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 35 studies in Breast Neoplasms by European Organisation for Research and Treatment of Cancer - EORTC are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Breast Neoplasms by European Organisation for Research and Treatment of Cancer - EORTC, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of multiple-fraction SBRT in patients with oligometastatic disease of primary breast, prostate, NSCLC and colorectal cancer having all lesions that will be treated with radical radiotherapy amenable to single-fraction SBRT.

The main question/hypothesis this clinical trial aims to answer is:

- Single-fraction SBRT has comparable outcomes as those obtained with multiple fraction SBRT, both in terms of safety and efficacy.

Patients from the OligoCare cohort will be randomized to receive either single-fraction SBRT or the current SoC of multiple-fraction SBRT.

Read the detailed description

As a consequence of improved survival of metastatic cancer patients due to more effective systemic therapy, focused radiotherapy in the form of stereotactic body radiotherapy (SBRT) has become a standard of care in many clinical situations to achieve durable symptom and / or metastasis control: treatment of brain metastases, of painful bone or spinal metastases and especially as local treatment in a multimodality treatment strategy for oligometastatic disease. These indications are supported by international practice guidelines, e.g. ESMO guidelines for NSCLC and colorectal cancer; and NCCN guidelines for NSCLC, prostate cancer, renal cell cancer, colorectal cancer and sarcoma.

However, despite the universal use of SBRT in the local treatment of oligometastases, the level of evidence supporting stereotactic radiotherapy is low, apart from few small prospective clinical trials showing a very favourable toxicity profile of SBRT and promising efficacy data. In this context, the OligoCare research project, a prospective observational cohort study, has been developed within the E²-RADIatE platform. The aim of this project is to collect real-world data on SBRT treatment of patients with oligometastatic disease of primary breast, prostate, lung and colorectal cancer, with no limit on the maximum number of treated metastases.

Yet, the local treatment of multiple metastases poses several challenges. One of them is the integration of local metastases-directed SBRT into a systemic treatment strategy: in an interim analysis of the OligoCare cohort, almost all patients were treated with fractionated SBRT and the median number of SBRT fractions was 5. This would result in a total of 50 SBRT fractions in a patient with 10 metastases. Considering that several drugs are paused before and after SBRT, the systemic therapy free interval could last for almost 2 months, which one could consider as unacceptably long in metastatic cancer patients.

One solution to this problem would be the delivery of radiotherapy in a smaller number of SBRT fractions, preferably as single-fraction SBRT. Single-fraction SBRT has been described since the 90's for treatment of liver metastases, lung metastases or vertebral metastases. A recent randomized phase II trial compared multiple-fraction vs single-fraction SBRT for pulmonary oligometastases (n=90) and did not observe differences in toxicity or any oncological outcome parameter.

Nevertheless, single-fraction SBRT still lacks adoption in the radiation oncology community. Likely reasons are the experience of single-fraction SBRT restricted to small, highly specialized centers, the small number of patients treated with single-fraction SBRT in the literature and the concerns of potentially increased toxicity and / or decreased efficacy.

There is consequently a strong rationale to implement and evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current SoC of multiple-fraction SBRT.

This question will be addressed in the current Trials within Cohorts (TwiCs) study, in which patients from the OligoCare cohort will be randomized to receive either single-fraction SBRT or the current SoC of multiple-fraction SBRT. The main hypothesis is that single-fraction SBRT has comparable outcomes as those obtained with multiple fraction SBRT, both in terms of safety and efficacy.

03

Conditions studied

  • Breast Cancer
  • Prostate Cancer
  • NSCLC
  • Colorectal Cancer
  • Oligometastatic Disease

Keywords

  • radiotherapy
  • SBRT
  • TwiCs
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is part of the RP1822-OligoCare. As in OligoCare, ALL active cancer lesions (loco-regional primary and all oligometastases) were or will be treated with radical intent (surgery or radiotherapy).
  • All lesions that will be treated with radical radiotherapy have to be amenable to single-fraction SBRT. Concurrent systemic treatment is allowed.
  • Written must be given according to ICH/GCP, and national/local regulations. Patients will be consented in a step-wise approach.

Step 1 [both control and experimental arms]: patients will need to consent to be included and evaluated in E²-RADIatE (that includes the non-interventional OligoCare prospective registry cohort) and to potentially be randomized to future sub-studies for which they are eligible; no further consent will be sought if they are randomized to the SoC (control) arm; Step 2 [experimental arm only]: if eligible for the current sub-study and randomized to receive single-fraction SBRT, patients will need to consent to receiving the experimental treatment.

Exclusion criteria

Exclusion Criteria:

All targeted lesion judged by the treating physician to be associated with risks for severe toxicity following single-fraction SBRT. The following lesions are systematically excluded:

  • Pulmonary within 1 cm of proximal bronchial tree, esophagus or brachial plexus
  • Metastases within \< 5 mm of any hollow GI structure: esophagus, stomach, small bowel, large bowel
  • Metastases within \< 5 mm of the spinal cord, the cauda equina or the brachial plexus
  • Metastases > 5 cm in largest diameter.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (estimated)

Study arms

  • Experimental
    single-fraction SBRT

    All lesions to be treated with radical radiotherapy will be treated with single-fraction SBRT, delivered using a dose ranging from 16 Gy to 34 Gy, depending on metastasis location. Acceptable ablative doses are developed in the protocol (see Section 6.4). Radiotherapy treatment will last from one single visit to a few weeks, depending on the number of treated metastases.

    Radiation: single-fraction SBRT

  • Active comparator
    multiple-fraction SBRT

    All lesions to be treated with radical radiotherapy will be treated with multiple-fraction SBRT.

    Radiation: multiple-fraction SBRT

Interventions

  • Radiationsingle-fraction SBRT

    Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.

  • Radiationmultiple-fraction SBRT

    Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.

06

What researchers measure

Primary outcomes

  1. Grade 3+ SBRT-related toxicity

    The cumulative incidence of grade 3+ SBRT-related toxicity within 12 months following treatment with radical radiotherapy. This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, for adverse event reporting.

    Time frame: within 12 months following treatment with radical radiotherapy.

Secondary outcomes

  1. Progression free survival (PFS)

    defined as the time from the date of randomization to the date of first progression (local, regional or distant) as per local assessment or death.

    Time frame: 4.5 years from first patient in

  2. Overall survival (OS)

    defined as the time from the date of randomization to the date of death from any cause.

    Time frame: 4.5 years from first patient in

  3. Local control (LC)

    defined as freedom from local metastasis (inside the PTV or prior treated field).

    Time frame: 4.5 years from first patient in

  4. Pattern of progression of primary disease and metastases

    Pattern of progression of primary disease and metastases includes local, regional and/or distant progression or recurrence.

    Time frame: 4.5 years from first patient in

Other outcomes

  1. Health-related Quality of life (HRQoL)

    The magnitude of change in HRQoL in terms of physical functioning from EORTC QLQ-C30.

    Time frame: 4.5 years from first patient in

  2. Health-related Quality of life (HRQoL)

    The magnitude of change in HRQoL in terms of pain/discomfort from EQ5D-5L questionnaires.

    Time frame: 4.5 years from first patient in

  3. Economic impact of radiation treatment

    To document the health economic impact of the two treatments by collecting Use of resources questionnaires during radiation treatment and during follow up.

    Time frame: 4.5 years from first patient in

07

Study locations

2 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2029, 46 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 46 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 17, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Feb 15, 2029
CompletionEst.
Feb 15, 2029
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06462963
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Apr 15, 2025
Primary completion
Feb 15, 2029 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Aug 1, 2025

Study contacts

EORTC HQ
Contact
eortc@eortc.org
+32 2 774 16 11
Matthias Guckenberger, MD
principal investigator · Radiation Oncology, University of Zurich, Switzerland
Piet Ost, MD
principal investigator · GZA Sint-Augustinus, Wilrijk, Belgium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion